Hypertension is a common complication of patient with chronic kidney diseases (CKD), and an important risk factor for the development of CKD. Therefore, controlling hypertension is one of the keys to block the progression of CKD. Since the release of 2012 edition "KDIGO clinical practice guideline for management of blood pressure (BP) in patient with chronic kidney disease", new clinical trials has been constantly emerging. Based on this, KDIGO has released a 2021 updated guide. The new guideline covers standardized BP measurements, lifestyle interventions without dialysis, BP management and medication recommendations, and for special CKD population, including kidney transplant patients and children, the corresponding BP management and medication recommendations are recommended. Compared with the previous guideline, standardized BP measurements in the clinic is a new addition. Furthermore, one of the most noteworthy is that the target BP of CKD patients without dialysis is systolic pressure <120 mmHg, which further demonstrates the benefits of intensive hypotensive therapy, but the recommendation level is only 2B. This article launches interpretation for the above several aspects in this new consensus.